| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $0 | 0 | 0 |
Sells | $368,042 | 25 | 100 |
| Smalling Ralph | Head of Regulatory | 0 | $0 | 6 | $5,420 | $-5,420 |
| Smither John W | director | 0 | $0 | 1 | $34,898 | $-34,898 |
| Yu Yong | SVP, Clinical Development | 0 | $0 | 5 | $37,796 | $-37,796 |
| Cappello Joseph | Chief Technical Officer | 0 | $0 | 5 | $39,253 | $-39,253 |
| Thomas John | director | 0 | $0 | 3 | $108,766 | $-108,766 |
| Zindrick Thomas | President and CEO | 0 | $0 | 5 | $141,909 | $-141,909 |
Genelux Corporation is a clinical-stage biopharmaceutical company focused on pioneering advanced oncolytic viral immunotherapies for patients confronting aggressive and/or hard-to-treat solid tumor malignancies. Its leading experimental drug, Olvi-Vec, is a proprietary, engineered vaccinia virus strain being developed to address ovarian cancer and non-small cell lung cancer. The company is also advancing V2ACT Immunotherapy for pancreatic cancer, alongside V-VET1 for the treatment of both hematologic and solid cancers. Founded in 2001, Genelux …
Over the last 12 months, insiders at Genelux Corporation have bought $0 and sold $368,042 worth of Genelux Corporation stock.
On average, over the past 5 years, insiders at Genelux Corporation have bought $536,625 and sold $4.19M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 2,500 shares for transaction amount of $10,000 was made by Yu Yong (VP, Clinical Trial Operations) on 2024‑05‑29.
| 2026-08-31 | Sale | Zindrick Thomas | President and CEO | 34,463 0.078% | $2.67 | $91,899 | -4.96% | |
| 2026-08-31 | Sale | Cappello Joseph | Chief Technical Officer | 10,257 0.0239% | $2.74 | $28,112 | -4.96% | |
| 2026-08-31 | Sale | Yu Yong | Chief Scientific Officer | 9,683 0.0226% | $2.75 | $26,658 | -4.96% | |
| 2026-08-04 | Sale | Zindrick Thomas | President and CEO | 3,023 0.007% | $2.95 | $8,905 | -10.46% | |
| 2026-08-04 | Sale | Cappello Joseph | Chief Technical Officer | 653 0.0015% | $2.95 | $1,924 | -10.46% | |
| 2026-08-04 | Sale | Yu Yong | Chief Scientific Officer | 653 0.0015% | $2.94 | $1,922 | -10.46% | |
| 2026-07-01 | Sale | Smither John W | director | 12,000 0.032% | $2.91 | $34,898 | -10.34% | |
| 2026-06-03 | Sale | Smalling Ralph | Head of Regulatory | 192 0.0005% | $2.93 | $563 | -10.33% | |
| 2026-06-01 | Sale | Thomas John | director | 10,000 0.0267% | $2.98 | $29,801 | -9.09% | |
| 2026-05-11 | Sale | Zindrick Thomas | President and CEO | 2,798 0.0075% | $2.94 | $8,226 | -5.69% | |
| 2026-05-11 | Sale | Cappello Joseph | Chief Technical Officer | 605 0.0016% | $2.97 | $1,799 | -5.69% | |
| 2026-05-11 | Sale | Yu Yong | Chief Scientific Officer | 605 0.0016% | $2.97 | $1,798 | -5.69% | |
| 2026-05-11 | Sale | Smalling Ralph | Head of Regulatory | 270 0.0007% | $2.98 | $804 | -5.69% | |
| 2026-03-25 | Sale | Smalling Ralph | Head of Regulatory | 240 0.0006% | $2.51 | $602 | +2.26% | |
| 2026-03-24 | Sale | Zindrick Thomas | President and CEO | 3,582 0.0095% | $2.42 | $8,668 | +11.57% | |
| 2026-03-24 | Sale | Cappello Joseph | Chief Technical Officer | 906 0.0024% | $2.42 | $2,193 | +11.57% | |
| 2026-03-24 | Sale | Yu Yong | SVP, Clinical Development | 906 0.0024% | $2.42 | $2,193 | +11.57% | |
| 2026-03-24 | Sale | Smalling Ralph | Head of Regulatory | 345 0.0009% | $2.42 | $835 | +11.57% | |
| 2026-03-02 | Sale | Thomas John | director | 10,000 0.0258% | $2.90 | $28,957 | -8.22% | |
| 2025-12-05 | Sale | Smalling Ralph | Head of Regulatory | 165 0.0004% | $4.69 | $774 | -41.27% |
| Zindrick Thomas | President and CEO | 1226427 2.7106% | $2.35M | 1 | 9 | <0.0001% |
| Thomas John | director | 472784 1.0449% | $907,745.28 | 1 | 7 | <0.0001% |
| Yu Yong | Chief Scientific Officer | 258688 0.5717% | $496,680.96 | 1 | 21 | <0.0001% |
| Smither John W | director | 91403 0.202% | $175,493.76 | 1 | 2 | <0.0001% |
| Smalling Ralph | Head of Regulatory | 67611 0.1494% | $129,813.12 | 1 | 11 | <0.0001% |
| Ryder Sean | General Counsel | 47621 0.1053% | $91,432.32 | 1 | 4 | <0.0001% |
| Tyree James L | director | 45791 0.1012% | $87,918.72 | 1 | 3 | <0.0001% |
| Zak Lourie S. | Chief Financial Officer | 40802 0.0902% | $78,339.84 | 1 | 1 | <0.0001% |
| Mirabelli Mary | director | 12460 0.0275% | $23,923.20 | 1 | 0 | <0.0001% |
| Zhang Qian | Associate VP, Research | 200 0.0004% | $384.00 | 1 | 0 | +278.21% |
$9,405,928 | 107 | 12.61% | $74.85M | |
$1,701,941 | 56 | 17.58% | $93.09M | |
$66,137,559 | 49 | 6.29% | $89.66M | |
$77,146,704 | 43 | 13.28% | $93.12M | |
$26,786,140 | 22 | -18.62% | $78.7M |
| Increased Positions | 40 | +71.43% | 2M | +23.36% |
| Decreased Positions | 16 | -28.57% | 150,183 | -2.01% |
| New Positions | 20 | New | 813,634 | New |
| Sold Out Positions | 4 | Sold Out | 56,948 | Sold Out |
| Total Postitions | 80 | +42.86% | 9M | +21.35% |
| Woodward Diversified Capital, Llc | $8,391.00 | 4.85% | 1.84M | +65,813 | +3.7% | 2025-09-30 |
| Vanguard Group Inc | $6,458.00 | 3.74% | 1.42M | -34,465 | -2.37% | 2025-09-30 |
| Bleichroeder Lp | $3,249.00 | 1.88% | 714,000 | 0 | 0% | 2025-09-30 |
| Blackrock, Inc. | $1,728.00 | 1% | 379,888 | +54,905 | +16.89% | 2025-09-30 |
| Geode Capital Management, Llc | $1,610.00 | 0.93% | 353,840 | +35,015 | +10.98% | 2025-09-30 |
| Bank Of America Corp /De/ | $1,472.00 | 0.85% | 323,494 | -85,198 | -20.85% | 2025-09-30 |
| Flputnam Investment Management Co | $1,366.00 | 0.79% | 300,290 | +263,131 | +708.12% | 2025-09-30 |
| Alyeska Investment Group, L.P. | $1,297.00 | 0.75% | 285,000 | 0 | 0% | 2025-09-30 |
| Global Retirement Partners, Llc | $1,040.00 | 0.6% | 228,676 | 0 | 0% | 2025-09-30 |
| Provident Wealth Management, Llc | $708.00 | 0.41% | 155,670 | -3,197 | -2.01% | 2025-09-30 |